Clinical Trial Update: Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS [Phase 2]

View source ↗

Summary

Phase 2 trial assessing repeated administration of NurOwn (MSC-NTF cells) for progressive multiple sclerosis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• NurOwn (MSC-NTF cells)

Snippet

Sponsor: Brainstorm-Cell Therapeutics | Conditions: Multiple Sclerosis, Chronic Progressive | Phase 2 | Status: COMPLETED | Results posted: 2022-11-14